-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OhEVRfemKyQD/4r5FvqMNIFWd+BgGHO09x/OCiOME1xs8HzITkaZQULXb35aCw84
 Ru0pAAyDmbmAE9Mo4C+fmw==

<SEC-DOCUMENT>0001104659-04-041332.txt : 20041228
<SEC-HEADER>0001104659-04-041332.hdr.sgml : 20041228
<ACCEPTANCE-DATETIME>20041228081859
ACCESSION NUMBER:		0001104659-04-041332
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041223
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041228
DATE AS OF CHANGE:		20041228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNOGEN INC
		CENTRAL INDEX KEY:			0000855654
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				042726691
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17999
		FILM NUMBER:		041227411

	BUSINESS ADDRESS:	
		STREET 1:		128 SIDNEY ST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6179952506

	MAIL ADDRESS:	
		STREET 1:		128 SIDNEY ST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a04-15325_18k.htm
<DESCRIPTION>8-K
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;font-weight:bold;margin:0in 0in .0001pt;padding:0in;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="border:none;font-weight:bold;margin:0in 0in .0001pt;padding:0in;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

</div>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;">UNITED STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d)</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date
of Report (Date of earliest event reported):&nbsp;&nbsp;<b><font style="font-weight:bold;">December 23,
2004</font></b></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ImmunoGen,
Inc.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact
name of registrant as specified in its charter)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.72%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Massachusetts</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-17999</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">04-2726691</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.72%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State
  or other jurisdiction of</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS
  Employer</font></p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.72%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File
  Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in .7pt 0in .7pt;width:31.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
  No.)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">128 Sidney Street, Cambridge, MA 02139</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address
of principal executive offices)&#160;&#160; (Zip
Code)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
telephone number, including area code:&nbsp;<b><font style="font-weight:bold;">&nbsp;(617)
995-2500</font></b></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (<i><font style="font-style:italic;">see </font></i>General
Instruction A.2. below):</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="1" style="font-size:3.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="1" style="font-size:3.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="1" style="font-size:3.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="1" style="font-size:3.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvalley\04-15325-1\task263087\15325-1-ba.htm',USER='tvalley',CD='Dec 27 13:14 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1.01.
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On December 23, 2004, ImmunoGen, Inc. and
Centocor, Inc. entered into a development and license agreement. Under the
terms of the agreement, Centocor will receive exclusive worldwide rights to
develop and commercialize anticancer therapeutics that comprise an antibody
developed by Centocor to an undisclosed tumor cell target and a maytansinoid
cell-killing agent developed by ImmunoGen.</font></p>

<p align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Centocor will be responsible
for the research, development, manufacturing, and marketing of any products
resulting from the license. ImmunoGen will receive from Centocor an upfront
payment of $1 million, up to an additional $42.5 million if certain
predetermined milestones are met, and royalties on the sales of any resultant
products, if and when any such sales occur. ImmunoGen is also entitled to
receive compensation from Centocor for product development research and the
production of preclinical and early clinical materials.</font></p>

<p style="margin:0in 0in .0001pt 30.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 9.01.
FINANCIAL STATEMENTS AND EXHIBITS</font></b></p>

<p style="margin:0in 0in .0001pt 30.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:1.0in;width:80.0%;">
 <tr>
  <td width="64" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.0pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit
  No.</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="40" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit</font></p>
  </td>
  <td width="358" valign="top" style="padding:0in 0in 0in 0in;width:268.8pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="64" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.0pt;">
  <p align="center" style="margin:12.0pt 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="398" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.15in;">
  <p style="margin:12.0pt 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;Press Release of ImmunoGen,
  Inc. dated December 28, 2004</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\tvalley\04-15325-1\task263087\15325-1-ba.htm',USER='tvalley',CD='Dec 27 13:14 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ImmunoGen,
  Inc.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant)</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: December 28, 2004</font></p>
  </td>
  <td width="216" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:162.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christopher U.
  Missling</font></p>
  </td>
  <td width="88" valign="top" style="padding:0in 0in 0in 0in;width:66.0pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christopher U. Missling</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer
  and Vice President, Finance</font></p>
  </td>
 </tr>
 <tr>
  <td width="304" valign="top" style="padding:0in 0in 0in 0in;width:227.75pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="304" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:228.25pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(principal financial and
  accounting officer)</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\tvalley\04-15325-1\task263087\15325-1-ba.htm',USER='tvalley',CD='Dec 27 13:14 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:1.0in;width:80.0%;">
 <tr>
  <td width="64" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.0pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit
  No.</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.8pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit</font></p>
  </td>
  <td width="353" valign="top" style="padding:0in 0in 0in 0in;width:265.0pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="64" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.0pt;">
  <p align="center" style="margin:12.0pt 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="24" valign="top" style="padding:0in 0in 0in 0in;width:.25in;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="398" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:4.15in;">
  <p style="margin:12.0pt 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;Press Release of ImmunoGen,
  Inc. dated December 28, 2004</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tvalley\04-15325-1\task263087\15325-1-ba.htm',USER='tvalley',CD='Dec 27 13:14 2004' -->


</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a04-15325_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="2" face="Times New Roman"><img width="208" height="26" src="g153251kgimage002.gif"></font></p>

<p style="border:none;line-height:3.0pt;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p style="line-height:6.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:9.0pt;letter-spacing:.1pt;">128
Sidney Street, Cambridge, MA 02139-4239&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TEL:
(617) 995-2500&#160;&#160; FAX: (617) 995-2510</font></p>

<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:9.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contacts</font></u></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="91%" style="border-collapse:collapse;margin-left:.5in;width:91.5%;">
 <tr>
  <td width="287" valign="top" style="padding:0in 0in 0in 0in;width:215.0pt;">
  <h1 style="font-weight:normal;margin:3.0pt 0in .0001pt;page-break-after:avoid;text-align:justify;text-decoration:underline;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Investors:</font></u></h1>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carol Hausner</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive Director,
  Investor Relations<br>
  and Corporate Communications</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: (617) 995-2500</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">info@immunogen.com</font></p>
  </td>
  <td width="267" valign="top" style="padding:0in 0in 0in 0in;width:200.0pt;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Media:</font></u></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tony Loke</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rx Communications Group,
  LLC</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel: (917) 322-2164</font></p>
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">tloke@rxir.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></u></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:6.0pt 0in 4.0pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ImmunoGen, Inc. Announces that
Centocor Has Licensed</font></b></p>

<p align="center" style="margin:6.0pt 0in 12.0pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certain Rights to ImmunoGen&#146;s
Tumor-Activated Prodrug Technology</font></b></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAMBRIDGE,
MA December 28, 2004</font></b><font size="2" style="font-size:10.0pt;"> &#151; ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology
company that develops targeted anticancer products, today announced that
Centocor has licensed certain exclusive rights to </font><font size="2" style="font-size:10.0pt;">ImmunoGen&#146;s Tumor-Activated Prodrug (TAP) technology.
Centocor is a wholly-owned subsidiary of Johnson &amp; Johnson and</font><font size="2" style="font-size:10.0pt;"> a leader in
antibody-based therapeutics</font><font size="2" style="font-size:10.0pt;">.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the agreement, Centocor will receive exclusive
worldwide rights to develop and commercialize anticancer therapeutics that
comprise a Centocor antibody that binds to an undisclosed cancer target and a
maytansinoid cell-killing agent developed by ImmunoGen. ImmunoGen&#146;s
cell-killing agents are designed specifically for antibody-directed delivery to
cancer cells.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Centocor will be responsible for the research, development, manufacturing,
and marketing of any products resulting from the license. ImmunoGen will
receive from Centocor an upfront payment of $1 million, milestone payments that
potentially total $42.5 million, and royalties on the sales of any resultant
product. ImmunoGen also will receive financial compensation for product
development research done on behalf of Centocor and for the production of
preclinical and early clinical materials for Centocor.</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mitchel Sayare, PhD, ImmunoGen Chairman and CEO, said, &#147;We are
delighted to enter into this collaboration with Centocor, a recognized leader
in antibody-based therapeutics. Centocor is the seventh major company that has
licensed the right to use our TAP technology, and we now have collaborations
with the three leaders in the development and commercialization of
antibody-based products: Centocor, Biogen Idec, and Genentech. These licenses
expand the number of TAP compounds in development, and help us fund our own
product programs.&#148;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-more-</font></p>

<div align="left" style="line-height:normal;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\04-15325-1\task263022\15325-1-kg.htm',USER='rcheney',CD='Dec 27 11:43 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="line-height:normal;margin:0in .9pt .0001pt 0in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ImmunoGen&#146;s TAP technology is designed to provide cancer-targeting
engineered antibodies with significant clinical activity. ImmunoGen attaches a
potent cell-killing agent to the antibody as a payload. The antibody serves to
carry the payload specifically to cancer cells, and the payload serves to kill
the cancer cells.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About ImmunoGen, Inc.</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ImmunoGen, Inc. develops
targeted anticancer biopharmaceuticals. The Company&#146;s proprietary TAP
technology uses cancer-targeting engineered antibodies to deliver a potent
cell-killing agent specifically to cancer cells. ImmunoGen is advancing its
wholly-owned TAP compounds, huN901-DM1 and huC242-DM4. Aventis, Genentech,
Biogen Idec, Boehringer Ingelheim, Centocor, Millennium Pharmaceuticals, Inc.,
and Abgenix have licensed the right to develop or test TAP compounds to
specific targets; ImmunoGen also has a broader collaboration with Aventis, part
of the sanofi-aventis Group. For additional information on ImmunoGen, please
visit www.immunogen.com.</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release includes forward-looking statements based
on management&#146;s current expectations. For these statements, ImmunoGen claims
the protection of the safe harbor for forward-looking statements provided by
the Private Securities Litigation Reform Act of 1995. Various factors could
cause the Company&#146;s actual results to differ materially from those discussed or
implied in the forward-looking statements and you are cautioned not to place
undue reliance on these forward-looking statements, which are current only as
of the date of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to: the outcome
of the Company&#146;s research and clinical development processes, including the
anticipated clinical advancement of huC242-DM4 and huN901-DM1; the outcome of
the Company&#146;s collaboration partners&#146; research and clinical development
processes, including the anticipated clinical advancement of partner compounds;
the difficulties inherent in the development of pharmaceuticals, including
uncertainties as to the timing, expense and results of preclinical studies and
clinical trials; the Company&#146;s dependence upon existing and potential
collaborative partners, and the outcome of the clinical testing of TAP
compounds being developed by the Company&#146;s existing partners; uncertainty as to
whether the Company&#146;s potential products or those of the Company&#146;s
collaborators will succeed in entering human clinical trials and uncertainty as
to the results of such trial; the risk that the Company and/or its
collaborators may not be able to obtain regulatory approvals necessary to
commercialize their product candidates; the potential development by
competitors of competing products and technologies; uncertainty whether the
Company&#146;s TAP technology will produce safe, effective and commercially viable
products; and other factors more fully described in ImmunoGen&#146;s Annual Report
on Form 10-K for the fiscal year ended June 30, 2004 and other reports filed
with the Securities and Exchange Commission.</font></i></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"># # #</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="left" style="margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\04-15325-1\task263022\15325-1-kg.htm',USER='rcheney',CD='Dec 27 11:43 2004' -->


</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g153251kgimage002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g153251kgimage002.gif
M1TE&.#=AT``:`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````T``:`(<```"`````@`"`@````("``(``@(#`P,#`W,"FRO`$!`0("`@,
M#`P1$1$6%A8<'!PB(B(I*2E5555-34U"0D(Y.3G_?(#_4%#6`)/,[/_OUL;G
MY]:MJ9`S``!F``"9``#,````,P`S,P!F,P"9,P#,,P#_,P``9@`S9@!F9@"9
M9@#,9@#_9@``F0`SF0!FF0"9F0#,F0#_F0``S``SS`!FS`"9S`#,S`#_S`!F
M_P"9_P#,_P```#,S`#-F`#.9`#/,`#/_`#,`,S,S,S-F,S.9,S/,,S/_,S,`
M9C,S9C-F9C.99C/,9C/_9C,`F3,SF3-FF3.9F3/,F3/_F3,`S#,SS#-FS#.9
MS#/,S#/_S#,S_S-F_S.9_S/,_S/__S,``&8S`&9F`&:9`&;,`&;_`&8`,V8S
M,V9F,V:9,V;,,V;_,V8`9F8S9F9F9F:99F;,9F8`F68SF69FF6:9F6;,F6;_
MF68`S&8SS&:9S&;,S&;_S&8`_V8S_V:9_V;,_V;_`,S,`/\`F9F9,YF9`)G,
M`)D``)DS,YEF`)G,,YG_`)D`9IDS9IEF,YF99IG,9IG_,YDSF9EFF9F9F9G,
MF9G_F9D`S)DSS)EFS&:9S)G,S)G_S)D`_YDS_YEFS)F9_YG,_YG__YD``,PS
M`)EF`,R9`,S,`,P`,YDS,\QF,\R9,\S,,\S_,\P`9LPS9LQF9IF99LS,9LS_
M9ID`F<PSF<QFF<R9F<S,F<S_F<P`S,PSS,QFS,R9S,S,S,S_S,P`_\PS_\QF
M_YF9_\S,_\S__\PS`,QF`/^9`/\`,\PS,_]F,_^9,__,,___,_\`9O\S9O]F
M9LR99O_,9O__9LP`F?\SF?]FF?^9F?_,F?__F?\`S/\SS/]FS/^9S/_,S/__
MS/\S__]F_\R9___,____9F9F_V;__V9F9O__9O]F__^E`"%?7U]W=W>&AH:6
MEI;+R\NRLK+7U]?=W=WCX^/JZNKQ\?'X^/C_^_"@H*2`@(#_````_P#__P``
M`/__`/\`______\(_P#_"1Q(L*#!@P@3*ES(L*%#@;RZ1>3UL*+%BQ@7\EI4
M9E?&CR!#-NP6R569,CQ0GC1CQE4MD1]=+7(%$^/)ES5SZGS(B];)E&46F1%J
MY@O*13LKNN*!-"E#7F9X>'1*E6JMJ$9=_J,(D5<DH549<C035J&9,CC+J@7)
MRU#6M1\C?:$)EV!;J77S#IR8$&K*2'HONOK")K#`FP*[#26;,-)0P/]H#:5[
M<.-0BC(I&_Q*T[(KK@9WF4DK4-S7DT;+1)I*L-9;BU==+7;%1BC=F9H+UG(%
MF:%KNKQDDM:]B/7`6H[/+F(3"73EJ%QKH?PB"6$W'E]XT"V:TCG!2-AY4/]<
MI#WA4J2\4I8_.)CQ5KG9%\UD@]5,-X(GRV`L^N6L__Q;3=>40;4PY9!)C!68
MW7`#L3%7:V5D=Q)'*#%8T%DX\=+?@P=%DE]3@T7HW4!EG%7&>$&95T9AO.1W
MXD&N]4:+4;WMY=]`NXB(T6`U&H1:1S"FV-!O`DD'X$$SIN5:4!$-U(U$"G5#
M'E>2!%74?05).==ZRI489&WB_;-4;M\9F-Y0)W58!ET%EE$=0D4Q!IX9(S;$
M$9E[3<@#G02NQY!)3>W"5)SLK5ED2G@V=-94NWQ1"T<]_M/-7-(UQ5&+?!8T
M&"]LO'BGBNAY>1:9,1YF:$*3HO4/1P,>M$LDR-7_(DDM.`U&2T+B,$E>I-(E
M2B"'E>:JVF8\X'22KQI%-96'DISI'4?-&O@/2QL5FV5_U8['0Z0#C;F5F306
MY"%-TGV!94+DT90NJN%EEQUC#OK:HGXY6MN:GPLA*)"@2+5IW*H/PG?N11@6
M^05%;CFGF'XM%K:J?M*Y)Y"'@''DT:<(`1I@@MBVYN@_KK6*D)$/([M;28X)
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M*\K6U`2BC[5L$48K7>Y0M[W(F$YDRIG8Q^32P,HL#2>=XHJP*'(2KES'$/\0
MQQ<&!!YR^6DI]FL;0=9E.X,(\'@TR='>W+8>DSQ.(042F[SXYZ1U:>]`7@)9
MV__F19.Z_:-*YOH(8L241.X5JU)Y(DO#\E2&A;&&(T`+XD'&IK^""$L2C8),
M\OIB%-:<Q8`*P1SWT&B02>T,*E_81:\<,J.F0+$@C:(3>(QUJHN\SF]`$H@D
MC**LO>R)%RU46XEX*"9K,8];)MG;\/JT2.!\880(:1$FG10A[?S++E\KWPXM
M]YT(><M.0<PA>P9%/B'VT2(G>=/X!G;&5J6M<3C:'&F,V,@U=2.!W8@D9'(D
M,8)HCF4!*B-H>&&DK7$D)6R@E42Z02M7N"6(6$/;5J@7PA$FL"`4.I4X:C$P
M37&H2EM3FBY+QR0O4D2.;[(+2B"3.M693U++^UZ`NF.\S/5XY9)`F0[AN"(H
M,WS3+EC13#<ZE1+.(2HADAB?N]0S45/RKJ$J`0K<C(*07&6'+A:%$T>/J$\(
M84<SY4H)FE!21'Z*JQ;1Z1$S98J<K=!*-S=M32V,8YJO+`=6!V5FZ^"&G!$Q
MTQ69<<4NRGD0DOAT*+C9Z3=WLQM:N,1L6A'34(-#BY=8#R&[R.JKXFD0292$
KJ<AA21D,T1*/[*:"AHGK4_*RQ[QH4ZYXS6M(Y'-0O?KUKX!U4IW^&A``.S\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
